News by subject: TRI

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from multiple clinical studies of the company's novel...

Melbourne ophthalmology company PolyActiva is developing a unique biodegradable ocular implant that provides 6 months of sustained drug delivery for patients with glaucoma, the second most common cause of irreversible blindness.The interim Phase 2a...

Lilly Canada is pleased to announce that Mounjaro®...

?  NDA submission initiated for revumenib in R/R KMT2Ar acute leukemia under RTOR  ? ?  mNPM1 final efficacy data from the Phase 1 portion of AUGMENT-101 demonstrates a 36% CR/CRh rate  ? ?  Revumenib and axatilimab U.S. registrational filings on...

Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced today its schedule of activities at the 2023 Radiological Society of North America (RSNA) Scientific Assembly and Annual Meeting from November 26-30...

MyOme, Inc., a pioneering clinical whole genome platform analysis company specializing in polygenic risk scores, will present data during the 2023 American Society of Human Genetics (ASHG) Annual Meeting taking place from...

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company")  a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced today that it has selected of Fortrea (FTRE) as the Company's...

DaVita Clinical Research (DCR), a wholly owned subsidiary of DaVita Inc., is presenting the findings of five new research projects at the American Society of Nephrology (ASN)'s annual "Kidney Week," which is currently underway in Philadelphia. The...

Updated data from the Phase I trial of RVU120 in relapsed/refractory acute myeloid leukemia (r/r AML) or high-risk myelodysplastic syndromes (HR-MDS) demonstrate clinically relevant benefit in 50% of evaluable patients Preclinical data support RVU120...

Rigel Pharmaceuticals, Inc.  today announced the upcoming presentation of four posters highlighting data from their commercial and clinical-stage hematology-oncology portfolio at the 65th American...

Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that several abstracts that include selinexor data in myelofibrosis (MF) have been selected for presentation at the 65th...

Precision Biologics, a clinical stage therapeutics company whose proprietary platform has produced highly targeted monoclonal antibodies, will deliver a poster presentation on preliminary results of the ongoing phase 2 trial, combining NEO-201...

CalciMedica Inc. ("CalciMedica") , a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic diseases, today...

Inhibrx, Inc. , a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced preliminary efficacy and safety data from the Phase 1 trial of INBRX-109 in combination with...

-      Relapsed or refractory AML patients with a TP53 mutation receiving Iomab-B led allogeneic bone marrow transplant had a median Overall Survival of 5.49 months compared to 1.66 months in patients that did not receive Iomab-B (hazard ratio=0.23,...

PacBio , a leading developer of high-quality, highly accurate sequencing solutions, today announced the creation of the HiFi Solves consortium. This global consortium brings together researchers from 15 leading genomics research institutions across...

STRM.BIO, a pre-clinical, VC-backed biotechnology company that is leveraging extracellular vesicles (EVs) to deliver gene therapies and developing new therapeutics for rare blood diseases, today announced that it will present preclinical data on...

Eli Lilly and Company today announced that data from studies of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition...

Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced that it will present a poster demonstrating the potential of its multiplex epigenetic editing platform at the American...

...

Syndax Pharmaceuticals , a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that results from the...

Arcellx, Inc. , a...

Vetigenics, a clinical-stage biopharmaceutical company advancing antibody-based therapies for pets, announces that the first canine patient with stage 4 oral melanoma has received his first dose of Vetigenics' fully canine anti-CTLA4 monoclonal...

Cytrellis Biosystems, a pioneer in novel medical aesthetic solutions and manufacturer of ellacor® and its proprietary Micro-Coring® Technology, announced today that six abstracts demonstrating ellacor safety and efficacy will be presented at the...

Ichnos Sciences Inc., a global clinical-stage biotechnology company developing innovative multispecific immune cell engager antibodies in oncology, today announced dosing of the first patient in the Phase 1 first-in-human clinical trial of ISB 2001,...

Neurocrine Biosciences, Inc. today announced interim results from the ongoing open-label KINECT®-HD2 study about INGREZZA® (valbenazine) capsules when used for the long-term treatment of adults with chorea associated with Huntington's disease (HD)....

QuantalX Neuroscience, a pioneering healthcare company dedicated to early detection of brain disorders, is pleased to...

Akeso (9926.HK) today announced that its collaboration and licensing partner, Summit Therapeutics Inc. ("Summit") will present data for the...

Apex Labs Ltd. (APEX or the Company), a pharmaceutical company transforming the standard of mental health care with psilocybin treatments is excited to announce the launch of its multi-dose Early Access Program (EAP) for APEX-90 macrodose...

Regulus Therapeutics Inc. , a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the dosing of the first patient in the third cohort of the...

Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech,i announced new findings from the Q-FFICIENCY study were published in the...

Amgen today announced new data for KRYSTEXXA® (pegloticase) showing a decrease in blood pressure during treatment of adults living with chronic gout refractory to oral urate-lowering treatment ? uncontrolled gout ? both with and without chronic...

I-Mab (the "Company"), a global biotechnology company focused on bringing...

Endo International plc announced today that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping colchicine 0.6 mg capsules, a generic version of Hikma's MITIGARE®. This is the first generic colchicine capsule approved by the...

Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy Haduviotm (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), refractory chronic...

In a total of 26 ibezapolstat-treated patients in Phases 2a and 2b, the Clinical Cure rate is 96%Meets protocol primary objective of assessing the primary efficacy endpoint of the Clinical Cure rate after 10 days of oral treatmentIbezapolstat was...

Intensity Therapeutics, Inc. , a...

- BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) shows meaningful clinical benefit in adult patients with BRAFV600-mutant advanced NSCLC - The application is based on results from the PHAROS study,[1] which showed an objective response rate of 75%...

Immunic, Inc. , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it has received a Notice of Allowance from the United...

Mission Therapeutics ("Mission"), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces that it will present an oral abstract on its experimental drug candidate MTX652 at the American Society of...

On Oct. 31, 2023, Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen" and with stock code 688321.SH) received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration ("NMPA")...

Kodiak Sciences Inc today announced that data from tarcocimab tedromer will be presented during the annual meeting of the American Academy of Ophthalmology (AAO) to be held November 3-6 in San Francisco. During the Retina Subspecialty Day on...

The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the last of four Late-Breaking Clinical Trial sessions at the VIVA23...

Xtalks, a division of Honeycomb Worldwide Inc., is excited to announce the launch of its groundbreaking magazine, Xtalks Clinical Edge. This magazine offers an exclusive look into the world of clinical trials, featuring interviews with key opinion...

The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the third of four Late-Breaking Clinical Trial sessions at the VIVA23...

Penumbra, Inc. , a global healthcare company focused on innovative therapies, announced the latest...

Researchers have genetically engineered the first mice that get a human-like form of COVID-19, according to a study published online November 1 in Nature....

Block Clinical Inc., a leading innovator in the clinical trial industry, is thrilled to announce an exciting partnership with Lyft Healthcare, to revolutionize the transportation experience for clinical trial participants. This collaboration marks a...

...

Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, reported that a poster with positive clinical...